Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques.
Animals
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
CD8-Positive T-Lymphocytes
/ immunology
COVID-19
/ immunology
Disease Models, Animal
Female
Humans
Kinetics
Lymphocyte Depletion
/ veterinary
Macaca fascicularis
/ immunology
Male
Monkey Diseases
/ immunology
RNA, Viral
/ genetics
SARS-CoV-2
/ genetics
Virus Replication
/ immunology
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
21
05
2021
accepted:
06
07
2021
revised:
29
07
2021
pubmed:
20
7
2021
medline:
6
8
2021
entrez:
19
7
2021
Statut:
epublish
Résumé
SARS-CoV-2 infection presents clinical manifestations ranging from asymptomatic to fatal respiratory failure. Despite the induction of functional SARS-CoV-2-specific CD8+ T-cell responses in convalescent individuals, the role of virus-specific CD8+ T-cell responses in the control of SARS-CoV-2 replication remains unknown. In the present study, we show that subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques. Eight macaques were intranasally inoculated with 105 or 106 TCID50 of SARS-CoV-2, and three of the eight macaques were treated with a monoclonal anti-CD8 antibody on days 5 and 7 post-infection. In these three macaques, CD8+ T cells were undetectable on day 7 and thereafter, while virus-specific CD8+ T-cell responses were induced in the remaining five untreated animals. Viral RNA was detected in nasopharyngeal swabs for 10-17 days post-infection in all macaques, and the kinetics of viral RNA levels in pharyngeal swabs and plasma neutralizing antibody titers were comparable between the anti-CD8 antibody treated and untreated animals. SARS-CoV-2 RNA was detected in the pharyngeal mucosa and/or retropharyngeal lymph node obtained at necropsy on day 21 in two of the untreated group but undetectable in all macaques treated with anti-CD8 antibody. CD8+ T-cell responses may contribute to viral control in SARS-CoV-2 infection, but our results indicate possible containment of subacute viral replication in the absence of CD8+ T cells, implying that CD8+ T-cell dysfunction may not solely lead to viral control failure.
Identifiants
pubmed: 34280241
doi: 10.1371/journal.ppat.1009668
pii: PPATHOGENS-D-21-01073
pmc: PMC8321216
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009668Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Pathog. 2015 Nov 04;11(11):e1005247
pubmed: 26536034
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Biochem Biophys Res Commun. 2021 Jan 29;538:125-131
pubmed: 33218685
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Jpn J Infect Dis. 2020 Jul 22;73(4):304-307
pubmed: 32074516
Cell. 2020 Aug 6;182(3):744-753.e4
pubmed: 32553273
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4
pubmed: 32333914
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
J Virol. 2014 Oct;88(19):11034-44
pubmed: 25056892
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Science. 2020 Nov 27;370(6520):1110-1115
pubmed: 33037066
Nat Commun. 2021 Feb 24;12(1):1260
pubmed: 33627662
Biochem Biophys Res Commun. 2021 Jan 29;538:211-217
pubmed: 33190827
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
J Clin Invest. 2021 Mar 1;131(5):
pubmed: 33427749
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Science. 2020 May 29;368(6494):1012-1015
pubmed: 32303590
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
J Virol. 2010 Feb;84(3):1289-301
pubmed: 19906920
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Sci Transl Med. 2021 May 12;13(593):
pubmed: 33820835
Nature. 2020 Sep;585(7824):268-272
pubmed: 32396922
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292